Chemotherapy for treatment of grade II gliomas

Research output: Contribution to journalReview article

Abstract

Gliomas classified as grade II by the World Health Organization (WHO) include astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. This heterogeneous group of conditions is associated with a more favorable prognosis and longer-term survival than high-grade gliomas (HGGs). Neurosurgical resection and radiation therapy improve survival in symptomatic, progressive, or high-risk grade II gliomas. Until recently, the role of chemotherapy has been less clear. This review draws on insights from the management of HGGs and emerging data on the addition of PCV (procarbazine, lomustine [CCNU], and vincristine) to radiation for these neoplasms. Specifically, this review focuses on the current status of chemotherapeutic management of grade II gliomas, including optimal timing of treatment, and management of 1p19q codeleted and non-codeleted tumors.

Original languageEnglish (US)
Pages (from-to)1036-1043
Number of pages8
JournalOncology (Williston Park, N.Y.)
Volume28
Issue number12
StatePublished - Dec 1 2014

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this